{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:00:11Z","timestamp":1740135611394,"version":"3.37.3"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1245\/s10434-020-08979-5","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T17:06:02Z","timestamp":1596647162000},"page":"1481-1482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ASO Author Reflection: Trends and Impact of Adjuvant Chemotherapy in Resected Gallbladder Cancer: Going Beyond Trial Data"],"prefix":"10.1245","volume":"28","author":[{"given":"Phillip M. Kemp","family":"Bohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1555-819X","authenticated-orcid":false,"given":"Daniel W.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"8979_CR1","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019;20:663\u201373.","journal-title":"Lancet Oncol"},{"key":"8979_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol 2019;37:1015\u201327.","journal-title":"J Clin Oncol"},{"key":"8979_CR3","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08973-x","author":"PM Kemp Bohan","year":"2020","unstructured":"Kemp Bohan PM, Kirby DT, Chick RC, et al. Adjuvant chemotherapy in resectable gallbladder cancer is underutilized despite benefit in node-positive patients. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08973-x.","journal-title":"Ann Surg Oncol"},{"key":"8979_CR4","doi-asserted-by":"crossref","unstructured":"Nakachi K, Konishi M, Ikeda M, et al. A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Jpn J Clin Oncol 2018;48:392-5.","DOI":"10.1093\/jjco\/hyy004"},{"key":"8979_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12885-015-1498-0","volume":"15","author":"A Stein","year":"2015","unstructured":"Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial): a randomized, multidisciplinary, multinational phase III trial. BMC Cancer 2015;15:564.","journal-title":"BMC Cancer"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08979-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-08979-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08979-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T23:35:19Z","timestamp":1628120119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-08979-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["8979"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-08979-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2020,8,5]]},"assertion":[{"value":"12 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Phillip M. Kemp Bohan and Daniel W. Nelson declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}